News Releases

Date Title and Summary View
November 14, 2022
– Results show the impact of attacks on mental health, daily activities, and quality of life in people living with HAE - – Real-world data demonstrate treatment burden associated with on-demand parenteral HAE therapies - CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Nov....
Additional Formats
November 7, 2022
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Nov. 7, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced it will...
Additional Formats
November 2, 2022
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Nov. 2, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted one newly-hired employee inducement options to purchase an aggregate of 2,000 shares of...
Additional Formats
October 31, 2022
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Oct. 31, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced positive phase 1...
Additional Formats
October 27, 2022
KalVista today announced the acceptance of multiple abstracts at the 2022 Annual Scientific Meeting for the American College of Allergy, Asthma & Immunology. KalVista Pharmaceuticals (NASDAQ:KALV) CAMBRIDGE, MA, USA, October 27, 2022 / EINPresswire.com / -- KalVista Pharmaceuticals, Inc....
Additional Formats
October 19, 2022
- The discovery and optimization of sebetralstat published in the Journal of Medicinal Chemistry - - Data on   absorption, metabolism, and excretion of sebetralstat reported in the journal Xenobiotica - CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Oct....
Additional Formats
October 17, 2022
– Current Board Chairman Martin Edwards , M.D. to Retire in Planned Transition - CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Oct. 17, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and...
Additional Formats
October 7, 2022
– Data examines patient perspectives on treatment outcome measures used in phase 3 KONFIDENT trial of sebetralstat - – Additional data show the impact of HAE on mental health, daily activities, and quality of life of people living with HAE - CAMBRIDGE, Mass....
Additional Formats
October 5, 2022
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Oct. 5, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted four newly-hired employees inducement options to purchase an aggregate of 18,000 shares of...
Additional Formats
October 4, 2022
- Safety signals observed will not yield targeted product profile – - No impact on Sebetralstat expected safety profile or Phase 3 KONFIDENT trial – - Oral Factor XIIa program to become primary focus for HAE prophylaxis - CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Oct....
Additional Formats
Displaying 1 - 10 of 37